Aspirin Responsiveness in Women at Risk for Cardiac Events

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Creighton University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Women at least 19 years old

• Taking 81 mg aspirin daily, non-enteric coated, for at least one month for the primary prevention of cardiovascular disease.

• Able and willing to provide informed consent

Exclusion Criteria:

• Pregnancy or breastfeeding

• Known CHD

• Currently taking clopidogrel or ticlopidine

• Use of heparin, warfarin, or glycoprotein IIb/IIIa inhibitors within previous 96 hours

• Allergy or hypersensitivity to salicylates

• Use of other OTC or prescription analgesics or anti-inflammatory medication in the past two weeks

• Currently participating in another investigational drug or device study